News
Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a ...
A spokesperson said: “Results from the STEP trials demonstrate that weight regain is likely once medication is stopped.
Novo Nordisk A/S (NYSE:NVO) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 18, Novo Nordisk A/S ...
Goldman Sachs GQG Partners International Opportunities GSIMX has the elements in place to continue to outperform, though the road could be bumpy at times.
China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...
Aging America may revive healthcare stocks after a rough year — discover why long-term trends point to a powerful rebound.
Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...
(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...
Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.
Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...
Founded in 1998, Genmab develops customised antibodies for use in cancer treatments. Historically, the group has licensed its technology and the commercialisation of its drugs to large pharma giants ...
Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results